Moreover, inhibiting CaMKII phosphorylation via microinjection of KN‐93—a CaMKII activation inhibitor—into the mPFC alleviated depression‐like behavior and cognitive deficits, but not anxiety‐like behavior. The gene discussed is CAMK2G; the disease is Cognitive impairment.